Deeplife
Deeplife creates digital twins of cell to accelerate drug discovery.
Developing a new drug today takes 15 years and $2B which is a massive public health issue especially when an outbreak occurs.
Deeplife uses deep learning to create digital twins of cells and predict, in silico, cells reaction to drugs, gene editing or environmental perturbations. With their proprietary technology, Deeplife saves up to four years for the identification of molecular triggers driving cells from a sick state to a healthy state.
Deeplife wants to shape the future of bio-engineering, starting today with the leaders in the pharmaceutical industry.
Founders
Jonathan Baptista
CEO, Deeplife
Experienced in managing international teams with an MSc in complex systems simulation
Jean-Baptiste Morlot
CTO, Deeplife
PhD in machine learning applied to genetics, pioneer in deep learning to decode sequencing data